Impact Therapeutics, Inc.

This study tested a new drug called IMP4297 in 93 women with advanced ovarian cancer that has a BRCA1 or BRCA2 gene mutation and has not responded to at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. The drug is taken …

This study looked at how healthy men absorb, process, and eliminate a single dose of the experimental cancer drug IMP4297. Six volunteers took a radioactive-labeled pill, and researchers measured the drug in blood, urine, and stool over time. The goal was to understand the drug's…

This study tested whether a 10 mg and a 20 mg capsule of the experimental drug IMP4297 are processed similarly by the body. It involved 28 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to check bioequivalence, not to treat any disea…

This study tested two different strengths (10 mg and 20 mg) of an experimental drug called IMP4297 in 36 healthy Chinese men. The goal was to see if the body processes both strengths the same way after a meal. This is a bioequivalence study, meaning it checks if the two versions …